Skip to main content

Table 3 Clinical and laboratory differences between baseline and the end of ketogenic phase

From: VLCKD: a real time safety study in obesity

Parameters

Baseline

End of phase 1

p value

Weight (kg)

94.38 ± 17.34

87.29 ± 15.99

 < 0.001

BMI (kg/m2)

34.98 ± 5.43

32.35 ± 5.02

 < 0.001

WC (cm)

106.16 ± 14.20)

99.24 ± 13.57

 < 0.001

HC (cm)

120.53 ± 10.81

115.91 ± 9.70

 < 0.001

WHR

0.88 ± 0.08

0.86 ± 0.09

 < 0.001

Blood Glucose (mg/dL)

88.04 ± 8.95

82.60 ± 10.08

0.072

Insulin (mg/dL)

17.35 ± 13.83

8.05 ± 5.48

0.286

HOMA—IR

3.80 ± 2.79

1.74 ± 1.29

0.332

Tot Chol (mg/dL)

170.20 ± 40.77

144.72 ± 30.61

 < 0.001

LDL Chol (mg/dL)

101.95 ± 29.11

81.40 ± 29.91

0.142

HDL Chol (mg/dL)

52.24 ± 12.17

49.86 ± 13.11

0.018

TG (mg/dL)

88.95 ± 30.77

86.14 ± 20.57

0.235

GFR (mL/min)

94.13 ± 19.00

89.00 ± 20.83

0.123

Creatinine (mg/dL)

0.77 ± 0.11

0.82 ± 0.16

 < 0.001

Azotemia (mg/dL)

30.44 ± 8.94

34.89 ± 10.60

0.001

Uricemia (mg/dL)

5.29 ± 1.45

6.23 ± 1.69

0.054

AST (U/L)

20.50 ± 6.60

20.92 ± 6.32

0.022

ALT (U/L)

23.43 ± 9.85

22.90 ± 12.15

0.001

GGT (U/L)

17.82 ± 6.48

14.72 ± 5.25

0.003

Calcemia (mg/dL)

9.70 ± 0.75

9.90 ± 0.61

0.056

Sodiemia (mmol/L)

140.34 ± 2.72

140.53 ± 2.22

0.001

Potassiaemia (mmol/L)

4.41 ± 0.30

4.43 ± 0.33

0.452

  1. Data are expressed as n or mean ± SD
  2. BMI body mass index, WC waist circumference, HC hip circumference, WHR waist-to-hip-ratio, HOMA-IR homeostasis model of assessment-IR, Tot Chol total cholesterol, LDL-chol low-dense-lipoprotein cholesterol, HDL-chol high dense lipoprotein cholesterol, TG triglycerides, GFR glomerular filtration rate, AST aspartate aminotransferase, ALT alanine transaminase, GGT gamma-glutamyl transferase